Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $2 at Maxim Group
-
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $4 at Maxim Group Ahead of Binary Event
-
Cytori Closes Rights Offering for Gross Proceeds of $10 Million
-
Cytori Announces Expiration of Oversubscribed Rights Offering
-
Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21
-
Cytori Therapeutics (CYTX): Cutting PT To $5 from $10 - Maxim
-
Cytori Therapeutics (CYTX) Prices 8.6M Common Stock Offering at $1.10/Share
-
Cytori Announces Pricing of $9.5M Public Offering of Common Stock
-
Cytori Therapeutics (CYTX) to Offer Common Stock via Maxim Group
-
Cytori Announces Proposed Public Offering of Common Stock
-
Cytori Therapeutics, Inc. (CYTX) PT Raised to $10 at Maxim Group on Closure of the Azaya Deal
-
Cytori Therapeutics (CYTX) Scleroderma Day Offers Compelling Data - Maxim Group
-
Maxim Group Reiterates Bullish View on Cytori Therapeutics (CYTX) Following Study Using ADRCs to Maxillofacial Bone Regeneration
-
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million
-
Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million
-
Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing
-
Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
-
Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering
-
Cytori Therapeutics (CYTX) Discloses $11M Rights Offering
-
Cytori Therapeutics (CYTX) Enters Agreements with Series A-1, A-2 Warrantholders; Updates on Cash Burn
-
Cytori Amends Corporate Warrant Agreements Simplifying Capital Structure and Updates on 2015 Operating Cash Burn Guidance
-
Pre-Open Stock Movers 10/27: (TRIV) (UQM) (BABA) Higher; (RRTS) (RCII) (MRVL) Lower (more...)
-
Cytori Therapeutics (CYTX) PT Trimmed to $5 at Maxim Group; 'Buy' Maintained
-
Cytori Therapeutics (CYTX) Prices Direct Offering at 77c/Unit
-
Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing
-
Cytori Therapeutics (CYTX) a Step Closer to Clinical Trials, Maxim Group Notes
-
Approval in China, Orphan Staus from EMA Bode Well for Cytori (CYTX); Maxim Affirms 'Buy' Rating
-
Increased BARDA Funding a Validation for Cytori (CYTX) ADRC Celution System, Maxim Group Says
-
Cytori Therapeutics (CYTX) Price Target Lifted to $6 at Maxim Group
-
UPDATE: Cytori Therapeutics (CYTX) FDA News Positive, Maxim Group Says; Sees New Strategy Emerging
-
Cytori Therapeutics (CYTX) Closes on $13.5M in Financing
-
Cytori Therapeutics (CYTX) Announces $13.5M Registered Direct Placement
-
Maxim Group Analyst Discusses Ebola Virus (TKMR) (CYTX)
-
Cytori (CYTX) Prices 7.02M Offering at $2.85/Share
-
Maxim Group Starts Cytori Therapeutics, Inc. (CYTX) at Buy

